Literature DB >> 25820616

Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.

Sharon E Hopcraft1, Matthew J Evans1.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) cell entry is a complex, multistep process requiring numerous host cell factors, including the tight junction protein claudin-1 (CLDN1). It is not known whether CLDN1 and the HCV glycoproteins physically interact. Therefore, the focus of this work was to study genetic interactions between CLDN1 and HCV. We used CRISPR technology to generate CLDN1 knockout (KO) Huh-7.5 cells, which could not be infected by genotype 2a Jc1 HCV unless CLDN1 expression was restored. Passage of Jc1-transfected CLDN1 KO cells resulted in the selection of a virus that could infect these cells. This virus encoded a single mutation, H316N (numbered relative to the HCV polyprotein), in the E1 glycoprotein. Whereas Jc1 H316N efficiently infected cells lacking CLDN1, such infection was blocked by an antibody targeting CLDN6, another member of the claudin family that is expressed in these cells. Furthermore, HuH6 cells, which express CLDN6, but not CLDN1, were infectable only with the mutant virus. Thus, this mutant virus adapted to the loss of CLDN1 by developing the capacity to utilize other CLDNs. Indeed, CLDN1/CLDN6 double-KO Huh-7.5 cells supported infection by the mutant virus only when CLDN1, CLDN6, or CLDN9 was expressed. Finally, this phenotype was not genotype dependent, given that the H316N mutation rendered a Japanese fulminant hepatitis 1 chimeric HCV genome encoding the genotype 5a glycoproteins able to utilize CLDN6 for host cell entry.
CONCLUSION: These data demonstrate plasticity of HCV virus-host interactions, where a previously CLDN1-dependent virus was capable of evolving to use CLDN6. They also reveal a role for E1 in determining entry factor usage and imply a direct, physical interaction between E1 and CLDNs.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820616      PMCID: PMC4587996          DOI: 10.1002/hep.27815

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  Hepatitis C virus host cell entry.

Authors:  Alexander Ploss; Matthew J Evans
Journal:  Curr Opin Virol       Date:  2012-01-04       Impact factor: 7.090

2.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

3.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

4.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

Review 5.  Entry and replication of recombinant hepatitis C viruses in cell culture.

Authors:  Gabrielle Vieyres; Thomas Pietschmann
Journal:  Methods       Date:  2012-09-23       Impact factor: 3.608

6.  Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.

Authors:  Isabel Fofana; Laetitia Zona; Christine Thumann; Laura Heydmann; Sarah C Durand; Joachim Lupberger; Hubert E Blum; Patrick Pessaux; Claire Gondeau; Gary M Reynolds; Jane A McKeating; Fritz Grunert; John Thompson; Mirjam B Zeisel; Thomas F Baumert
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

7.  The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus.

Authors:  Laurent Meertens; Claire Bertaux; Lisa Cukierman; Emmanuel Cormier; Dimitri Lavillette; François-Loïc Cosset; Tatjana Dragic
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

8.  Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.

Authors:  Florian Douam; Viet Loan Dao Thi; Guillemette Maurin; Judith Fresquet; Dimitri Mompelat; Mirjam B Zeisel; Thomas F Baumert; François-Loïc Cosset; Dimitri Lavillette
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

9.  Bile acids specifically increase hepatitis C virus RNA-replication.

Authors:  Patrick Chhatwal; Dorothea Bankwitz; Juliane Gentzsch; Anne Frentzen; Philipp Schult; Volker Lohmann; Thomas Pietschmann
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

10.  Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies.

Authors:  Marion Sourisseau; Maria L Michta; Chati Zony; Benjamin Israelow; Sharon E Hopcraft; Christopher M Narbus; Ana Parra Martín; Matthew J Evans
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

View more
  21 in total

1.  A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Authors:  Adam Zuiani; Kevin Chen; Megan C Schwarz; James P White; Vincent C Luca; Daved H Fremont; David Wang; Matthew J Evans; Michael S Diamond
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Authors:  Rehab I Moustafa; Juliano G Haddad; Lydia Linna; Xavier Hanoulle; Véronique Descamps; Ahmed Atef Mesalam; Thomas F Baumert; Gilles Duverlie; Philip Meuleman; Jean Dubuisson; Muriel Lavie
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

3.  Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.

Authors:  Yoshimi Shimizu; Yoshitaka Shirasago; Masuo Kondoh; Tetsuro Suzuki; Takaji Wakita; Kentaro Hanada; Kiyohito Yagi; Masayoshi Fukasawa
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 4.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 5.  Systems Proteomics View of the Endogenous Human Claudin Protein Family.

Authors:  Fei Liu; Michael Koval; Shoba Ranganathan; Susan Fanayan; William S Hancock; Emma K Lundberg; Ronald C Beavis; Lydie Lane; Paula Duek; Leon McQuade; Neil L Kelleher; Mark S Baker
Journal:  J Proteome Res       Date:  2016-01-12       Impact factor: 4.466

6.  Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.

Authors:  Juliano G Haddad; Yves Rouillé; Xavier Hanoulle; Véronique Descamps; Monzer Hamze; Fouad Dabboussi; Thomas F Baumert; Gilles Duverlie; Muriel Lavie; Jean Dubuisson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

7.  Sec24C-Dependent Transport of Claudin-1 Regulates Hepatitis C Virus Entry.

Authors:  Peiqi Yin; Ye Li; Leiliang Zhang
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 8.  Claudins in viral infection: from entry to spread.

Authors:  Che C Colpitts; Thomas F Baumert
Journal:  Pflugers Arch       Date:  2016-11-24       Impact factor: 4.458

9.  Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process.

Authors:  Yasmine Baktash; Anisha Madhav; Kelly E Coller; Glenn Randall
Journal:  Cell Host Microbe       Date:  2018-03-14       Impact factor: 21.023

Review 10.  Tight junction proteins in gastrointestinal and liver disease.

Authors:  Mirjam B Zeisel; Punita Dhawan; Thomas F Baumert
Journal:  Gut       Date:  2018-10-08       Impact factor: 31.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.